Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Japanese Children Aged 6 Months to 17 Years.
Phase of Trial: Phase II
Latest Information Update: 05 May 2017
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 23 Feb 2010 Actual number of patients added to 60 as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2010 Actual end date added to 1 Dec 2009 as reported by ClinicalTrials.gov.